Fleboton® 150 mg/3 ml + 1.5 mg/3 mi 

Solution for injection

Composition: 3 ml of solution for injection containing 150 mg Troxerutin and 1.5mg Carbazochrome.

Properties: Troxerutin (3-hydroxyethyl-rutoside), also known as vitamin P4, is a bioflavonoid that acts by increasing yasal resistance (capillary protective a*ction) and diminishing permeability, thus preventing the excessive leakage of the liquid component of blood to tissues (anti-permeabilising and anti- edemigenic a*ction). Carbazochrome (adenochromosemicarbazone), an orthoquinone derived from adrenalin through oxidation and lateral chain cycling, is totally devoid of sympathomimetic a*ction, owing to the absence of the secondary amine function and the ortho-diphenolic grouping, and it shortens the haemorrhage time through a local vasoconstrictive a*ction on small vessels in the bleeding area.

Therapeutic Indications: Symptomatic venous insufficiency; states of capillary fragility in post-hemorrhoidectomy patients.

Posology and m*ethod of administration: 1-3 ampoules a day by intramuscular injection. The content of the ampoules must not be mixed with solutions containing ascorbic acid.

Contraindications: Hypersensitivity to the active substances or to any of the excipients.

Special warnings and precautions for use: None.

Intera*ctions with other medicinal products and other forms of intera*ction: None reported.

Pregnancy and lactation: For Fleboton® no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.

Effects on ability to drive and use machines: Fleboton® has no influence on the ability to drive and use machines.

Undesirable effects: Some cases of local and generalised erythema have been reported in patients receiving Fleboton® solution for injection via the intradermic or subcutaneous route (mesotherapy). The use of Fleboton® solution for injection in mesotherapy is not approved since there are no controlled clinical studies showing the efficacy and safety of these m*ethods of administration.

Overdose: No case of overdose has been reported.

Incompatibilities: Fleboton® solution for injection should not be mixed with ascorbic acid.

Manufactured by MINAPHARM Egypt

MINAPHARM